Sizing Biotech Binary Events: A Framework for Readout Risk

If you find yourself trying to predict a biotech readout, stop. The honest move is to admit you can't — and then size the position so the outcome doesn't ruin you either way. This post is about the second part.

A "binary event" in biotech is any catalyst with a roughly two-state outcome: a Phase 2 or Phase 3 trial result, an FDA advisory committee vote, a PDUFA decision, or a major label expansion. The stock typically moves 40-80% on the day. Sometimes more. The point of the framework below is not to outsmart the readout — it's to make sure your position size reflects what you actually know, which is less than you think.

Why predicting biotech readouts is a losing game

Base rates are humbling. Across oncology, drugs face substantial attrition from Phase 1 through approval; the broader industry average across therapeutic areas sits near 10-15%. Phase 3 success rates hover around 50-60%, but conditional on a drug surviving that long, the market has already priced in a lot of optimism.

The deeper problem is that the variables that determine a readout — biomarker behavior, placebo response, dropout rates, statistical noise around a primary endpoint — are not things a non-specialist can model. Even specialist hedge funds with PhDs on staff are wrong often enough that they build portfolios, not single bets.

The reader's edge, if there is one, is not in predicting the result. It's in:

• Understanding what is already priced in.
• Knowing the asymmetry of the payoff.
• Sizing the position so a wrong answer is survivable and a right answer is meaningful.

How to read implied moves and what the market expects

Before sizing anything, figure out what the options market is pricing. The implied move — derived from at-the-money straddles expiring just after the catalyst — gives you the market's expected magnitude of the move, not the direction.

For a typical Phase 3 readout in a mid-cap biotech, implied moves of 40-60% are common. For a smaller single-asset company, 70%+ is not unusual. Compare that to the implied move on a large-cap earnings event, which is usually 4-8%. The order-of-magnitude difference tells you everything about the risk profile.

A few practical reads:

• If the implied move is much larger than your expected upside in the bull case, the trade is already crowded. You're paying for optionality the market has already noticed.
• If the implied move is smaller than the historical move for comparable readouts, either the market thinks the result is more certain than usual, or you've found a mispricing. Usually the former.
• Skew matters. If puts are dramatically more expensive than calls, the smart money is hedging downside. That's information.

You don't need to trade options to use them. The implied move is a free read on consensus expectations.

A position-sizing framework for binary catalysts

Here's a simple structure. Define three numbers before the readout:

1. Your subjective probability of success (p). Be honest. If you don't have a view better than the FDA's published base rates, use 50-60% for Phase 3, 30-40% for Phase 2, lower for novel mechanisms. Don't pretend to 80% conviction.
2. The expected up-move and down-move. Use the implied move as a starting point, then adjust. Single-asset companies fall harder on failure (60-80%) than they rise on success (40-60%), because failure often means the company is worth cash minus burn.
3. The maximum loss you'll accept on the position.

Apply a fractional Kelly sizing rule — Kelly is a formula that tells you the bet size that maximizes long-run growth given an edge. Full Kelly is too aggressive for binary events because your edge estimate is itself uncertain. Use one-quarter Kelly or less. In practice this usually lands position sizes at 1-3% of portfolio for a single binary, even when you feel strongly.

A worked example: you think a Phase 3 readout has a 55% chance of success, with +50% upside and -65% downside. Expected value is positive (about +5%), but the variance is enormous. Quarter-Kelly sizing here is roughly 2% of portfolio. Anything above 5% is gambling, not investing.

Structuring the trade around the readout

Sizing is half the work. Structure is the other half.

• Stock vs. options. Buying stock outright caps your loss at the position size but exposes you to the full downside move. Buying call options caps loss at premium paid but means you're long volatility into an event where IV is already elevated — you can be right on direction and still lose money as IV collapses post-event. Spreads (e.g., a call spread financed by a put sale) can cut premium cost but reintroduce downside.
• Pre-position vs. post-readout. A legitimate strategy is to skip the readout entirely and buy on the post-failure crater, when companies sometimes trade below cash. The window after a failure is often more analyzable than the readout itself.
• Pair trades. If you have a view on a mechanism rather than a specific drug, owning one name and shorting a competitor going into overlapping readouts neutralizes some of the binary risk.

What to watch next

• Check the implied move on any biotech you own with a catalyst in the next 90 days. If it's above 40%, treat the position as binary regardless of how confident you feel.
• Write down your probability estimate before the readout, along with your up/down move assumptions. Review after. This is the only way to calibrate over time.
• Cap single-name binary exposure at a level where a -70% move is annoying but not portfolio-defining. For most readers that's 1-3%.
• Consider buying post-failure in names where the cash position is meaningful and the pipeline isn't single-asset. The forced selling can create real mispricings.